Meda has acquired a portfolio of well established OTC products from the Swedish company BioPhausia. These products consist of strong brands such as Novalucol, Novalucid, C-vimin and Resulax. The acquisition price is 190 MSEK.
Meda’s ambition is to establish a strong position within the OTC area. The total turnover of Meda’s OTC products has grown steadily over the last years and today account for about 1.5 billion SEK.
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
